Evidence map›Paper›PMID 38070063›Full record

ArticleAngiogenesis2024

Circulating Von Willebrand factor: a consistent biomarker predicting in-hospital mortality across different waves of the COVID-19 pandemic.

David M Smadja, Anne-Sophie Jannot, Aurélien Philippe, Estelle Lu, Jeanne Rancic, Olivier Sanchez, Richard Chocron, Nicolas Gendron, Jean-Luc Diehl

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Angiogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David M SmadjaParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France. david.smadja@aphp.fr.
Anne-Sophie JannotMedical Informatics, Biostatistics and Public Health Department, Centre de Recherche des Cordeliers, AP-HP, Georges Pompidou European Hospital, European Georges Pompidou Hospital, AP-HP.CUP, University Paris Cité, Paris, France.
Aurélien PhilippeParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.
Estelle LuMedical Informatics, Biostatistics and Public Health Department, Centre de Recherche des Cordeliers, AP-HP, Georges Pompidou European Hospital, European Georges Pompidou Hospital, AP-HP.CUP, University Paris Cité, Paris, France.
Jeanne RancicParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.
Olivier SanchezParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.
Richard ChocronEmergency department, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.
Nicolas GendronParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.
Jean-Luc DiehlParis Cité University, Innovative Therapies in Hemostasis, INSERM, 75006, Paris, France.

Funding

Agence Nationale de la Recherche SARCODOMécénat Crédit Agricole Ile de France programme jeune talents
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19PandemicsBiomarkersHospital MortalityHumansvon Willebrand FactorBiomarkersvon Willebrand Factor

Identifiers

PMID38070063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.